The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The problem is there are a shed load of shares that the lucky few got at 5p that can be dumped for easy profit. other than more snouts at the trough so far we have had zero news...
Amran - I'm not sure that CBX over-hyped it. I would point the finger at a number of posters here that got caught up in the excitement, bought on the initial spike and spent weeks spouting misinformation in order to get out with their shirts on their backs.
The company could do well but it will be entering a playing field populated by more and more suppliers. The reality is that they don't have the celebrity endorsement of DB (despite what many constantly state as fact) and don't really have anything unique at this moment (there are plenty of synthetic CBD suppliers, companies with special serum products and a number of companies targeting the sports market). At this point in time we don't know what the branding will be and have no idea of where it will be sold.
Jacksdad states that first estimates are for 250,000 customers (which he says is conservative) - where are those estimates from and what are they based on? That sounds very rampy to me and when statements like that are made they need to be backed up otherwise they carry no weight.
The danger is that people's expectations at the moment are too great for where the company is. Calls for RNS releases and revenues show a lack of understanding as the company does not yet have products. This is an early stage and patience should be rewarded - those hoping to make a quick buck now have missed the boat if they didn't get their IPO allocation. The old adage of sell in May and go away could be very apt here as it's unlikely that there will any major rises or falls in the SP for a while yet.
Well at least we’re getting rns’s now lol
We can't have revenue streams without a product
We can't have products without a team.
My view is that the board state autumn for first products. So if they stick to that plan then all is on track "as planned". That's fine with me. Delays would another story.
Always a long term hold, so not worth watching it everyday. Seems fair to assume that when products are for sale, that should help the share price.
Actual sales, revenue generation and cash collection is the next big hurdle. Interested to see demand for these products. Time will tell.
Rick.
hopefully, first rns announced and a 5% drop in share price, does not really make sense.
Should see this start to move...some have clearly missed the USP here. Fully synthetic lab manufactured cannabinoid. Peter Wall on the BOD and celebrity endorsed by DB. Next news will be around a distribution deal IMO. Forecasting initial client numbers of 250000 which I think is conservative.
Looks like they have some great people on board.
Regulatory experience invaluable.
Moving forward.
New appointments